Skip to content
Sign in

Company

Takeda Pharmaceutical

Open structure map

Description

Takeda

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue.

Wikipedia · CC BY-SA 4.0

Headquarters
JP
Reporting currency
JPY
Website
Website

Structure of Takeda Pharmaceutical

Takeda Pharmaceutical

Company

14 connections
UpstreamSupply and dependency
PeersCompetition and partners2 of 5
ConstraintsRegulation and exposure4 of 5
OwnershipInvestment and holdings
DownstreamCustomers2 of 4
OwnProducts and technology
Relationship began2026
Takeda PharmaceuticalCompany · 14 connections
Layer 1

UpstreamSupply and dependency1

DownstreamCustomers2

PeersCompetition and partners2

OwnershipInvestment and holdings4

OwnProducts and technology1

ConstraintsRegulation and exposure4

Place in the network

No. 1902 of 118934top 2%down 350 places this week

10 direct links

Weighted by public relations with evidence, recomputed daily.

Relations

Money between companies

Who invests in, owns, acquires or finances whom, from the relations AiSeek holds with evidence.

湘南ヘルスイノベーションパークownsKeros Therapeutics, I…financesTakeda Pharmace…

Lines show that a relation exists and which way it points; their thickness carries no amount. Dots only move to show the direction.

Arrows show the direction of the relationship. Filter to focus on a business area.

Showing 1 to 8 of 23

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 9
partners withInnovent

Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center

PR Newswire news releases · GDELT Global Knowledge Graph · 2026-11-16 16:00

View evidence
  • CompanyPR Newswire news releases2026-11-16 16:00
    Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center
    View source
  • CompanyPR Newswire news releases2026-11-16
    Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center
    View source
  • CompanyPR Newswire news releases2026-11-13
    Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center
    View source
  • CompanyPR Newswire news releases2026-10-26 17:18
    Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center
    View source
  • MediaGDELT Global Knowledge Graph2026-10-25 18:45
    View source
  • CompanyPR Newswire news releases2026-10-25 14:00
    Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
    View source
  • CompanyPR Newswire news releases2026-10-25 14:00
    Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion.
    View source
  • MediaGDELT Global Knowledge Graph2026-10-23 22:45
    View source
  • MediaGDELT Global Knowledge Graph2026-10-23 18:30
    View source
FactEvidence 1
peak revenue targetup to $11 billion

No public evidence summary is available.

Nikkei Asia · 2026-10-30 01:29

View evidence
FactEvidence 1
rate exposureinterest rates

No public evidence summary is available.

GDELT Global Knowledge Graph · 2026-10-29 15:15

View evidence
  • MediaGDELT Global Knowledge Graph2026-10-29 15:15
    View source
FactEvidence 1
geographic exposureJapan

No public evidence summary is available.

GDELT Global Knowledge Graph · 2026-10-29 15:15

View evidence
  • MediaGDELT Global Knowledge Graph2026-10-29 15:15
    View source
FactEvidence 1
regulatory exposureDrug pricing rules

No public evidence summary is available.

GDELT Global Knowledge Graph · 2026-10-29 15:15

View evidence
  • MediaGDELT Global Knowledge Graph2026-10-29 15:15
    View source

Showing 1 to 6 of 40

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Filings

Source: EDINET disclosure site (Financial Services Agency of Japan) · Public Data License 1.0 · Figures extracted and reorganised by AiSeek.

Suggest a page to watch

Know a page of this company that matters, such as pricing, a changelog, terms or careers? Suggest it. We read every suggestion; a page we add is watched for everyone, and we only count a change when two looks in a row agree.

Sign in to suggest a page

Not available: Company signals · Financials · Sites · Guidance